Liquid Biosciences has developed a highly advanced bio-analytics platform that has been operational for over a decade, focusing on the discovery and validation of novel biomarkers across a wide range of diseases. The company has successfully completed 170 projects in healthcare, collaborating with 35 leading biopharma, diagnostic, clinical research, and academic institutions globally. Their innovative approach has not only led to the identification of hundreds of novel biomarkers but has also played a crucial role in rescuing failed drug candidates and accelerating the development of new therapeutics. This rapid and effective methodology positions Liquid Biosciences as a leader in the bio-analytics field, emphasizing their commitment to patient-centric solutions.

The expertise of Liquid Biosciences is further underscored by the extensive experience of its leadership team, particularly CEO Patrick Lilley, who has a rich background in biotech and technology innovation. With a portfolio that includes the invention of 75 technology patents and trade secrets in areas such as bioinformatics and high-performance algorithms, the company is at the forefront of integrating advanced technologies into healthcare solutions. Their focus on high-performance computing and tissue sample quality control enhances the reliability and efficiency of their bio-analytics platform, ensuring that they remain a pivotal player in the ongoing evolution of healthcare analytics.

United States

We are a leader in ushering the era of precision medicine by integrating and analyzing a broad set of patient data, utilizing proprietary algorithms and multi-omics assays, to better predict clinical outcomes and guide early intervention for customers such as pharmaceutical, biotech companies, and healthcare providers.

Liquid Biosciences

Company Details